Korea United Pharm Inc. (KRX:033270)
19,420
+380 (2.00%)
At close: Nov 26, 2025
Korea United Pharm Revenue
Korea United Pharm had revenue of 39.95B KRW in the quarter ending September 30, 2015, with 6.10% growth. This brings the company's revenue in the last twelve months to 161.44B, up 8.00% year-over-year. In the year 2014, Korea United Pharm had annual revenue of 155.19B with 13.37% growth.
Revenue (ttm)
161.44B
Revenue Growth
+8.00%
P/S Ratio
1.77
Revenue / Employee
242.76M
Employees
665
Market Cap
285.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2014 | 155.19B | 18.30B | 13.37% |
| Dec 31, 2013 | 136.89B | 2.06B | 1.53% |
| Dec 31, 2012 | 134.83B | -10.62B | -7.30% |
| Dec 31, 2011 | 145.45B | 10.47B | 7.76% |
| Dec 31, 2010 | 134.98B | 15.89B | 13.35% |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |